The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd’s generic version of Roche Holding AG’s cancer drug Xeloda. Teva Pharmaceuticals USA, a unit of the generic drugmaker, will market 150 and 500 milligram doses of the oral drug, named capecitabine. The drug, like Xeloda, will have a boxed warning about an increased risk of bleeding in patients who are on blood thinners .
Help employers find you! Check out all the jobs and post your resume.
